You are here

  • Home
  • Archive
  • Volume 9, Issue 4
  • Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials

Authors

  • Zi-Xian Wang Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, P. R. China PubMed articlesGoogle scholar articles
  • Hao-Xiang Wu Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, P. R. China Department of Clinical Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China PubMed articlesGoogle scholar articles
  • Li Xie Clinical Research Center, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China PubMed articlesGoogle scholar articles
  • Wu-Hao Lin Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, P. R. China PubMed articlesGoogle scholar articles
  • Fei Liang Department of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai, P. R. China PubMed articlesGoogle scholar articles
  • Jin Li Department of Medical Oncology, Tongji University Shanghai East Hospital, Shanghai, P. R. China PubMed articlesGoogle scholar articles
  • Zhi-Min Yang Medical Review Division 1, Center for Drug Evaluation, National Medical Products Administration, Beijing, P. R. China PubMed articlesGoogle scholar articles
  • Rui-Hua Xu Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, P. R. China PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Rui-Hua Xu; xurh{at}sysucc.org.cn
View Full Text

Citation

Wang Z, Wu H, Xie L, et al
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials
Journal for ImmunoTherapy of Cancer 2021;9:e002114. doi: 10.1136/jitc-2020-002114

Publication history

  • Accepted February 21, 2021
  • First published April 1, 2021.
Online issue publication 
April 01, 2021

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.